Clinical & Industry News

BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...

DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.

EuroPCR Hot Line Science features positive outcomes from the largest international head-to-head comparative trial of TAVR.

SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...

EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.

Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.

Newly issued patents in Australia and Japan cover the company's Artero™ E-IVL and Sola™ L-IVL platforms as FastWave advances toward peripheral and coronary IDE trials.

The eLym System is an investigational catheter-based device for treating patients with acute decompensated heart failure (ADHF) by supporting lymphatic drainage.

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026    Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...